Skip to Main Content
Advertisement
Close
The Journal of Immunology
ImmunoHorizons
Collections
AAI.ORG
FAQs
Predatory Publishing FAQ
Site FAQ
Publishing Partnership FAQ
Reduced Author Fees FAQ
Search Dropdown Menu
header search
search input
Search input auto suggest
filter your search
All Content
ImmunoHorizons
Search
Advanced Search
User Tools Dropdown
Register
Sign In
Toggle Menu
Menu
Articles
Current Issue
Archive
On the Horizon
Editorials
Immunology Education
About IH
About ImmunoHorizons
Journal Policies
Authors
Submit
Instructions to Authors
Journal Policies
Editors
IH Editorial Board
The JI
FAQs
Predatory Publishing FAQ
Site FAQ
Publishing Partnership FAQ
Reduced Author Fees FAQ
Skip Nav Destination
Guselkumab More Effectively Neutralizes Psoriasis-Associated Histologic, Transcriptomic, and Clinical Measures than Ustekinumab
Immunohorizons
(2023) 7 (4): 273–285.
Currently there are no citedby results. Try again later.
Close Modal
Close Modal
This Feature Is Available To Subscribers Only
Sign In
or
Create an Account
Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to
our privacy policy.
Accept
